Holen Sie sich die Stockscreener-App
10.55
0.00%
0.00
Handel nachbörslich:
10.70
0.15
+1.42%
Schlusskurs vom Vortag:
$10.55
Offen:
$10.51
24-Stunden-Volumen:
829.30K
Relative Volume:
0.47
Marktkapitalisierung:
$1.20B
Einnahmen:
$655.35M
Nettoeinkommen (Verlust:
$-136.23M
KGV:
-8.6313
EPS:
-1.2223
Netto-Cashflow:
$-75.68M
1W Leistung:
+1.83%
1M Leistung:
-19.10%
6M Leistung:
-27.24%
1J Leistung:
-36.02%
1-Tages-Spanne:
$10.44
$10.69
1-Wochen-Bereich:
$10.25
$11.30
52-Wochen-Spanne:
$9.82
$20.06
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
10.55 | 1.20B | 655.35M | -136.23M | -75.68M | -1.2223 |
ABT
Abbott Laboratories
|
102.30 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.30 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.28 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.19 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer - Sahm
JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (038.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
NovoCure Limited (NVCR) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR - marketbeat.com
NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer - MSN
NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed? - Yahoo Finance
NovoCure Ltd to release first quarter 2026 financial results on April 30 - Traders Union
Novocure to Report First Quarter 2026 Financial Results - Yahoo Finance
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages - marketbeat.com
NovoCure’s EF-32 Optune® Trial Reaches Completion, Setting Up a Key Catalyst for NVCR Investors - TipRanks
A Look At NovoCure (NVCR) Valuation After Extended Share Price Weakness - simplywall.st
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $49 - Moomoo
NovoCure Ltd (NVCR) Stock Price, Quote, News & History - Benzinga
NovoCure Limited Files 8-K Report Detailing Tumor Treating Fields Therapy and Corporate Information March 2026 - Minichart
Vanguard disaggregates ownership reporting for Novocure (NVCR) after realignment - stocktitan.net
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Does Positive PANOVA-4 Data Alter the Bull Case For NovoCure’s TTFields Platform (NVCR)? - simplywall.st
Brain Cancer Market Growth in Future Scope 2026-2033 | Novocure, - openpr.com
Novocure (NVCR) Reports Positive Phase 2 Results for TTFields Th - GuruFocus
Novocure (NVCR) Achieves Key Milestone in Pancreatic Cancer Tria - GuruFocus
Novocure reports positive Phase 2 trial results for pancreatic cancer By Investing.com - Investing.com India
Novocure stock rises on positive pancreatic cancer trial data By Investing.com - Investing.com Australia
PANOVA-4 Phase 2 trial shows promising TTFields therapy results, NovoCure Ltd reveals - Traders Union
Novocure (NASDAQ: NVCR) reports positive PANOVA-4 pancreatic cancer data - Stock Titan
Pancreatic cancer trial posts 74.4% disease control with Novocure - Stock Titan
Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump - Yahoo Finance
Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Position Lifted by Algert Global LLC - MarketBeat
Capital World Investors Lowers Holdings in NovoCure Limited $NVCR - MarketBeat
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
NovoCure Limited $NVCR Shares Acquired by American Century Companies Inc. - MarketBeat
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com South Africa
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - Sahm
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat
Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat
NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares - MarketBeat
NVCR Crosses Above Key Moving Average Level - Nasdaq
Tax-driven sale: NovoCure (NVCR) ex-CMO offloads 1,100 shares to cover RSU taxes - stocktitan.net
NovoCure (NVCR) General Counsel receives new stock options and RSU grants - Stock Titan
NovoCure (NASDAQ: NVCR) CMO reports tax sale and new stock awards - Stock Titan
Mukund Paravasthu sells Common shares via Morgan Stanley (NVCR) - stocktitan.net
[144] NovoCure Ltd SEC Filing - Stock Titan
NVCR (NASDAQ) Form 144: Insider-related sales include 3,272 and 7,461 shares - Stock Titan
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):